Enhancing T Cell Immune Responses by B Cell-based Therapeutic Vaccine Against Chronic Virus Infection |
Kim, Min Ki
(System Immunology Laboratory, Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University)
Lee, Ara (System Immunology Laboratory, Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University) Hwang, Yu Kyeong (Cell Therapy Team, Mogam Biotechnology Institute) Kang, Chang-Yuil (College of Pharmacy, Seoul National University) Ha, Sang-Jun (System Immunology Laboratory, Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University) |
1 | Bendelac, A., P. B. Savage, and L. Teyton. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25: 297-336. DOI ScienceOn |
2 | Fuchs, E. J., and P. Matzinger. 1992. B cells turn off virgin but not memory T cells. Science 258: 1156-1159. DOI |
3 | Schultze, J. L., S. Michalak, M. J. Seamon, G. Dranoff, K. Jung, J. Daley, J. C. Delgado, J. G. Gribben, and L. M. Nadler. 1997. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Iinvest. 100: 2757-2765. DOI ScienceOn |
4 | Coughlin, C. M., B. A. Vance, S. A. Grupp, and R. H. Vonderheide. 2004. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103: 2046-2054. DOI ScienceOn |
5 | Lapointe, R., A. Bellemare-Pelletier, F. Housseau, J. Thibodeau, and P. Hwu. 2003. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 63: 2836-2843. |
6 | Godfrey, D. I., S. Stankovic, and A. G. Baxter. 2010. Raising the NKT cell family. Nat. Immunol. 11: 197-206. DOI ScienceOn |
7 | Godfrey, D. I., and M. Kronenberg. 2004. Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114: 1379-1388. DOI |
8 | Kronenberg, M. 2005. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23: 877-900. DOI ScienceOn |
9 | Park, S. H., and A. Bendelac. 2000. CD1-restricted T-cell responses and microbial infection. Nature 406: 788-792. DOI ScienceOn |
10 | Chung, Y., B. S. Kim, Y. J. Kim, H. J. Ko, S. Y. Ko, D. H. Kim, and C. Y. Kang. 2006. CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo. Cancer Res. 66: 6843-6850. DOI ScienceOn |
11 | Kim, Y. J., H. J. Ko, Y. S. Kim, D. H. Kim, S. Kang, J. M. Kim, Y. Chung, and C. Y. Kang. 2008. alpha-Galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity. Int. J. Cancer 122: 2774-2783. DOI ScienceOn |
12 |
Hermans, I. F., J. D. Silk, U. Gileadi, M. Salio, B. Mathew, G. Ritter, R. Schmidt, A. L. Harris, L. Old, and V. Cerundolo. 2003. NKT cells enhance |
13 |
Stober, D., I. Jomantaite, R. Schirmbeck, and J. Reimann. 2003. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted |
14 | Wherry, E. J., J. N. Blattman, K. Murali-Krishna, R. van der Most, and R. Ahmed. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77: 4911-4927. DOI |
15 | Cerundolo, V., J. D. Silk, S. H. Masri, and M. Salio. 2009. Harnessing invariant NKT cells in vaccination strategies. Nat. Rev. Immunol. 9: 28-38. DOI ScienceOn |
16 | Ha, S. J., S. N. Mueller, E. J. Wherry, D. L. Barber, R. D. Aubert, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2008. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J. Exp. Med. 205: 543-555. DOI ScienceOn |
17 | Zajac, A. J., J. N. Blattman, K. Murali-Krishna, D. J. Sourdive, M. Suresh, J. D. Altman, and R. Ahmed. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188: 2205-2213. DOI |
18 | Ha, S. J., E. E. West, K. Araki, K. A. Smith, and R. Ahmed. 2008. Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol. Rev. 223: 317-333. DOI ScienceOn |
19 | Virgin, H. W., E. J. Wherry, and R. Ahmed. 2009. Redefining chronic viral infection. Cell 138: 30-50. DOI ScienceOn |
20 | Jin, H. T., Y. H. Jeong, H. J. Park, and S. J. Ha. 2011. Mechanism of T cell exhaustion in a chronic environment. BMB Rep. 44: 217-231. DOI ScienceOn |
21 | Ng, C. T., L. M. Snell, D. G. Brooks, and M. B. Oldstone. 2013. Networking at the level of host immunity: immune cell interactions during persistent viral infections. Cell Host Microbe 13: 652-664. DOI ScienceOn |
22 | Fahey, L. M., E. B. Wilson, H. Elsaesser, C. D. Fistonich, D. B. McGavern, and D. G. Brooks. 2011. Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. J. Exp. Med. 208: 987-999. DOI ScienceOn |
23 | Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915. DOI ScienceOn |
24 | Schultze, J. L., S. Grabbe, and M. S. von Bergwelt-Baildon. 2004. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol. 25: 659-664. DOI ScienceOn |
25 | Figdor, C. G., I. J. de Vries, W. J. Lesterhuis, and C. J. Melief. 2004. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10: 475-480. DOI ScienceOn |
26 | Janikashvili, N., N. Larmonier, and E. Katsanis. 2010. Personalized dendritic cell-based tumor immunotherapy. Immunotherapy 2: 57-68. DOI |
27 | King, C. C., R. de Fries, S. R. Kolhekar, and R. Ahmed. 1990. In vivo selection of lymphocyte-tropic and macrophage-tropic variants of lymphocytic choriomeningitis virus during persistent infection. J. Virol. 64: 5611-5616. |
28 | Eynon, E. E., and D. C. Parker. 1992. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J. Exp. Med. 175: 131-138. DOI ScienceOn |
29 | Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687. DOI ScienceOn |
30 | Elsaesser, H., K. Sauer, and D. G. Brooks. 2009. IL-21 is required to control chronic viral infection. Science 324: 1569-1572. DOI ScienceOn |
31 | Frohlich, A., J. Kisielow, I. Schmitz, S. Freigang, A. T. Shamshiev, J. Weber, B. J. Marsland, A. Oxenius, and M. Kopf. 2009. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 324: 1576-1580. DOI ScienceOn |
32 | Yi, J. S., M. Du, and A. J. Zajac. 2009. A vital role for interleukin-21 in the control of a chronic viral infection. Science 324: 1572-1576. DOI ScienceOn |
33 | Linterman, M. A., L. Beaton, D. Yu, R. R. Ramiscal, M. Srivastava, J. J. Hogan, N. K. Verma, M. J. Smyth, R. J. Rigby, and C. G. Vinuesa. 2010. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J. Exp. Med. 207: 353-363. DOI ScienceOn |
34 | Wiesner, M., C. Zentz, C. Mayr, R. Wimmer, W. Hammerschmidt, R. Zeidler, and A. Moosmann. 2008. Conditional immortalization of human B cells by CD40 ligation. PLoS One 3: e1464. DOI ScienceOn |
35 | Zotos, D., J. M. Coquet, Y. Zhang, A. Light, K. D'Costa, A. Kallies, L. M. Corcoran, D. I. Godfrey, K. M. Toellner, M. J. Smyth, S. L. Nutt, and D. M. Tarlinton. 2010. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J. Exp. Med. 207: 365-378. DOI ScienceOn |
36 | Sharpe, A. H., and G. J. Freeman. 2002. The B7-CD28 superfamily. Nat. Rev. Immunol. 2: 116-126. DOI ScienceOn |
37 |
Wherry, E. J., S. J. Ha, S. M. Kaech, W. N. Haining, S. Sarkar, V. Kalia, S. Subramaniam, J. N. Blattman, D. L. Barber, and R. Ahmed. 2007. Molecular signature of |
![]() |